DDInter1719 DDInter105
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Sugammadex {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Sugammadex {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Sugammadex {u} may lead to a major life threatening interaction when taken with {v} Norelgestromin
Sugammadex {u} may lead to a major life threatening interaction when taken with {v} Desogestrel
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sugammadex may lead to a major life threatening interaction when taken with Norelgestromin
Sugammadex may lead to a major life threatening interaction when taken with Desogestrel